Related Experiment Videos
Mechanisms of tissue injury in multiple sclerosis: opportunities for neuroprotective therapy
S Pouly1, J P Antel, U Ladiwala
1Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Quebec, Canada. mbar@musica.mcgill.ca
Abstract:
Development of neuroprotective therapies for multiple sclerosis is dependent on defining the precise mechanisms whereby immune effector cells and molecules are able to induce relatively selective injury of oligodendrocytes (OLs) and their myelin membranes. The selectivity of this injury could be conferred either by the properties of the effectors or the targets. The former would involve antigen specific recognition by either antibody or T cell receptor of the adaptive immune system. OLs are also susceptible to non antigen restricted injury mediated by components of the innate immune system including macrophages/microglia and NK cells. Target related selectivity could reflect the expression of death inducing surface receptors (such as Fas or TNFR-1) required for interaction with effector mediators and subsequent intracellular signaling pathways, including the caspase cascade. Development of therapeutic delivery systems, which would reach the site of disease activity within the CNS, will permit the administration of inhibitors either of the cell death pathway or of effector target interaction and opens new avenues to neuroprotection approach.
Insights
Understanding how immune cells damage oligodendrocytes (OLs) in multiple sclerosis is key to developing neuroprotective therapies. Targeting these mechanisms offers new treatment avenues for CNS injury.
Area of Science:
- Neuroimmunology
- Neurobiology
- Demyelinating Diseases
Background:
- Multiple sclerosis (MS) involves immune-mediated damage to oligodendrocytes (OLs) and myelin.
- The precise mechanisms of this selective injury are not fully understood.
- Identifying these mechanisms is crucial for developing effective neuroprotective therapies.
Purpose of the Study:
- To elucidate the mechanisms of selective oligodendrocyte injury in MS.
- To explore how immune effector cells and molecules induce damage.
- To identify potential therapeutic targets for neuroprotection in the central nervous system (CNS).
Main Methods:
- Investigated both adaptive (antibody, T cell receptor) and innate (macrophages/microglia, NK cells) immune pathways.
- Examined target-related selectivity through death-inducing surface receptors (e.g., Fas, TNFR-1).
- Considered intracellular signaling pathways, including the caspase cascade.
Main Results:
- Oligodendrocyte injury in MS can be mediated by both antigen-specific adaptive immunity and non-antigen-restricted innate immunity.
- Target selectivity may involve the expression of death receptors on OLs.
- Intracellular signaling pathways like the caspase cascade are implicated in OL death.
Conclusions:
- Defining the mechanisms of OL injury is essential for MS neuroprotection.
- Therapeutic strategies could target effector-target interactions or intracellular cell death pathways.
- Developing CNS-targeted delivery systems for inhibitors offers a promising approach to neuroprotection.